Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2017-06-15
Target enrollment:
Participant gender:
Summary
This study is being performed to assess the safety, tolerability, and preliminary clinical
effects of BVD-523 given orally, twice daily for 21-day cycles, in patients with Acute
Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).